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Abstract
Background: Acute tryptophan depletion (ATD) is a well-established dietary method in translational brain
research used to briefly lower central nervous serotonin (5-hydroxytryptamine (5-HT)) synthesis. A simplified two
amino acid ATD formula (ATDPHE/LEU) was developed while reducing the overall amount of amino acids (AAs),
with the objective of administration especially in children and adolescents in future studies.
Objective: This study investigated tryptophan (TRP) influx rates across the blood-brain barrier (BBB) after dietary
ATDPHE/LEU administration relative to the ATD Moja-De protocol that has been established for use in children and
adolescents.
Design: Seventy-two healthy adults (50% females) were randomized into four groups and administered ATD
Moja-De, its TRP-balanced control condition (BAL), ATDPHE/LEU, or its respective control mixture
(BALPHE/LEU) in a counterbalanced, double-blind, between-subjects design. Blood samples were collected at
baseline and at hourly intervals for 6 h after AA intake. Questionnaires about mood, taste, and challenge
tolerance were completed at fixed time points.
Results: Both challenge mixtures significantly reduced central nervous TRP influx as calculated by Michaelis
Menten kinetics relative to baseline and the respective control conditions with only mild and comparable side effects.
A greater decline in TRP influx over the BBB after ATDPHE/LEU administration when compared with ATD Moja-
De was detected without group effects for taste, challenge tolerance, and mood. There was unintended initial short
increase in plasma TRP concentrations observed after ATDPHE/LEU intake, and a possible redistribution between
free and protein-bound TRP triggered by protein synthesis stimulated by the ingested AAs may account for this
finding. Moreover, a decline in TRP influx after BALPHE/LEU administration over a 6-h periodwas observed, and the
large amount of PHE in the BALPHE/LEU mixture may be a possible explanation for this particular phenomenon,
which could have led to an unexpected increase in displacement of TRP at the BBB in this control condition.
Conclusions: This pilot study provides preliminary evidence for the possibility of lowering TRP influx as calculated
by MichaelisMenten kinetics into the brain by using a simplified ATD protocol in humans. The simplified
composition of only two AAs, the lower overall AA amount, and the appropriate tolerance are characteristics of the
newly developed ATDPHE/LEU protocol. Future studies focusing on the effects of the ATDPHE/LEU protocol and its
respective control condition on CSF 5-HIAA concentrations, as well as neurochemical studies in rodents, are
needed to further validate this newly developed AA mixture before definite conclusions about its usability in ATD-
related research in humans, its specificity, and additional effects can be made.
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cute tryptophan depletion (ATD) is an established
dietary challenge procedure used to investigate the
central nervous effects of the neurotransmitter
serotonin (5-hydroxytryptamine (5-HT)) in humans and
rodents by a short term and reversible reduction in the
brain 5-HT synthesis rate. This method has been com-
monly used in translational brain research for more than
25 years and is of both clinical and scientific relevance,
particularly because 5-HT modulates an extensive range of
physiological and behavioral functions (1). Moreover, it is
known to be involved in the pathogenesis and pathophy-
siology of a variety of different behaviors and neuropsy-
chiatric disorders, including affective, eating, and attention
deficit hyperactivity disorders (213).
ATD is accomplished through the administration of a
mixture of large neutral amino acids (LNAAs) lacking
tryptophan (TRP). Because 5-HT is not able to pass the
blood-brain barrier (BBB), it is synthesized from its
physiological precursor, the amino acid (AA) TRP, in the
brain. A small proportion of TRP reaches the central
nervous system through passive diffusion. The majority of
free TRP uses the active transport system L-1, a carrier in
the capillary cell plasma membrane specialized for the
transportation of all LNAAs, to cross the BBB (14). An
affinity to the aforementioned AA, increased by 1001,000
times, characterizes the BBB-specific type of the L-1
system (15). Moreover, L-systems differing in these and
other properties can be found in all cell types in the human
body (e.g. gastrointestinal tractus and hepatic and renal
tissues). The uptake of TRP into the brain using L-1, which
is saturated under physiological conditions, marks a
facilitated diffusion that follows MichaelisMenten ki-
netics with competitive substrate inhibition of the LNAAs
at the common transporter (1517). When orally admin-
istering a beverage of LNAAs lacking TRP, it was shown
that TRP plasma concentrations decline because of
increased protein synthesis in the liver, which is induced
by the administered AA load. Based on preliminary
findings in rats (18), this is thought to be an underlying
principle of the ATD challenge procedure introduced by
Young et al. because of reduced substrate availability for
brain 5-HT synthesis with regard to reduced plasma TRP
levels. Moreover, ATD makes use of the outlined compe-
titive substrate inhibition, resulting in a diminished uptake
of endogenous TRP into the central nervous system at
L-1 (1923). Specifically, the administered AAs com-
pete with endogenous TRP at L-1 for uptake into the
central nervous system. The synthesis of 5-HT in the
brain comprises two steps: first, the hydroxylation of
TRP by the tryptophan hydroxylase 2 (TPH2) into
5-hydroxytryptophan, followed by a 5-hydroxytryptophan
decarboxylase catalysis in the second step, which leads to
5-HT (24, 25). TPH2 is involved in the rate-limiting
step of the central nervous 5-HT synthesis pathway, with
TPH2 showing a saturation of approximately 50% under
physiological conditions (26). As a consequence, reduced
substrate availability of TRP due to competing mechan-
isms at the L-1 when other AAs are administered leads to a
lowered central nervous 5-HT synthesis rate. As outlined
above, AA administration is thought to induce restricted
5-HT synthesis by stimulating protein synthesis in the liver
with the consumption of additional TRP from plasma
stores (26, 27).
The history of ATD development is characterized
by avariety of modifications of the respective AA mixtures.
In 1977, Concu et al. (28) applied the ATD technique
to humans using 18.2 g of a TRP-free mixture (con-
taining L-glycine, L-lysine (LYS), L-methionine (MET),
L-phenylalanine (PHE), L-leucine (LEU), L-isoleucine
(ILE), L-threonine (THR), and L-valine (VAL)). They
detected a decline in serum TRP by 42% in healthy men
(29). Moja et al. (30) also tested a similar formulation,
lacking glycine, in healthy male subjects. In their study,
plasma TRP decreased to 35% of the initial level
following the administration of an AA dose of 36.6 g.
Most of the published ATD studies refer to a protocol
introduced by Young et al. (31). Young and colleagues used
a 100 g mixture of 15 amino acids (nine LNAA and six
non-essential AAs) and found a 76% decrease in plasma
TRP. This formulation can cause a large range of side
effects (such as nausea, vomiting, headache, and dizziness),
which were also reported in other ATD studies (2, 20, 3235).
Dougherty et al. (21) found that reducing the amino
acid dose to only 50 g helped diminish observed side effects
while implying a slightly less robust depletion when com-
pared with the 100 g formulation.
ATD Moja-De, a modification of the formulation by
Moja et al. (30), was developed in 2002 (36, 37) with the
aim of establishing a body weight-adapted dosing regi-
men that can be used in minors. This concept does
not only help to reduce side effects to a tolerable level
but also allows the application of ATD Moja-De to
children and adolescents as well as adults, opening further
developmental research perspectives for future studies.
Moreover, ATD Moja-De is the only available ATD formu-
lation to date that has been shown to decrease brain 5-HT
in mice (38).
Based on the above mentioned developments, we
decided to establish a new formulation, called ATDPHE/
LEU, for optimizing TRP depletion procedures in healthy
adult humans. Once data in adult humans are obtained as
proposed in this study, this formulation could potentially
be used for future studies in children and adolescents. Our
motivation was to introduce a new protocol for a possible
later use in children and adolescents allowing a reduction
of the overall AA amount and a less complex composition,
leading to a solid depletion magnitude while reducing
or maintaining the very low side effects established in
ATD Moja-De. Hence, a new protocol was developed
based on mathematical considerations and existing data
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that showed differing affinities of competing AAs to
L-1 (16), thus impacting TRP influx over the BBB to
the greatest extent. ATDPHE/LEU was intended to consist
of two AAs, PHE and LEU, as these show the highest
affinities to the L-1 transporting enzyme of all competing
LNAAs (16, 36). Therefore, based on a recent study con-
firming the effectiveness of a similar simplified protocol in
a mouse model (12), we expected adequate stimulation of
protein synthesis in the liver (thus leading to a decline in
plasma TRP) and a more effective displacement of TRP by
PHE and LEU at the common BBB transporter.
The primary aim of this study was to make a comparison
of the new dietary depletion protocol’s efficacy against that
of the established ATD Moja-De, contrasting challenge
conditions (ATD, ATDPHE/LEU) and their counterba-
lanced control conditions (BAL, BALPHE/LEU) in healthy
adults. We collected several blood samples over a defined
time interval and calculated TRP influx rates across the
BBB using MichaelisMenten kinetics with a correction
for multiple substrate inhibition.
Methods
Study design
The study employed a controlled, double-blind, between-
subjects design. One of the four different AA mixtures,
ATD Moja-De, BAL (a TRP-balanced AA load serving
as a control condition for ATD Moja-De), ATDPHE/LEU
(the new ATD AA mixture), or BALPHE/LEU (the newly
developed control condition for ATDPHE/LEU), was admi-
nistered to a sample group of healthy adult subjects. Blood
samples were collected at hourly intervals for 6 h.
Participants also completed questionnaires on mood,
challenge tolerance, and taste evaluations.
Ethics statement
The ethics committee of the Medical Faculty of the RWTH
Aachen University, Germany, evaluated and approved the
study protocol. The study was carried out in accordance
with the Declaration of Helsinki. All participants provided
oral and written informed consent. After completion of all
measurements, participants were financially compensated.
Sample
Participants were recruited through local advertisements.
A total of 72 subjects (50% females) aged between 18 and
33 years (mean age 23.6093.08 years) participated in the
study. All subjects were right-handed native German
speakers who did not suffer from any physical (excluded
by interview) or psychiatric disorder (evaluated by a
standardized screening interview for psychiatric disorders,
the SKIDPIT-light (39)). The exclusion criteria included
the following: an IQ lower than 85; smoking; the use of
regular medications excluding oral contraceptives; drug
abuse; pregnancy; psychoorganic syndromes; schizophrenia;
affective disorders; and neurological and somatic diseases
such as migraines, asthma, diabetes, metabolic or hormo-
nal disorders, allergies or obesity. The mean BMI of the
participants was 22.492.5 kg/m2. Using the CFT-20R
(40), the participants’ IQ (mean IQ112913.6) was
assessed. Approximately 20 individuals were excluded by
these criteria during the recruitment process. Primary pre-
screening for inclusion/exclusion criteria was conducted
by telephonic interview. Written informed consent was
obtained after in-person screening and clarification by
a doctor. Subjects verified by self-report that they
had followed the instructions regarding beverage and
food intake. Negative urine drug screens and pregnancy
tests were required before the administration of the AA
beverages. The complete descriptive data of the sample are
given in Table 1.
Depletion procedure
Measurements began at the same time each morning
in order to avoid the influence of circadian rhythms on
metabolism and central nervous 5-HT synthesis. The AA
beverages were administered between 9:00 and 10:00 a.m.
The study duration was approximately 6 h. The partici-
pants were instructed to abstain from food high in protein
beginning at 8:00 p.m. the night before each study day,
and they were not allowed to drink any beverages other
than water. They received a standardized low-protein
breakfast (carbohydrate 68.3 g, fat 1.13 g, protein 5.1 g,
and dietary fiber 2.3 g) containing two wheat rolls as well
as one small pack of jam (25 g) and honey (25 g)
immediately following the administration of the AA
beverages with a 20-min time frame for breakfast. The
particular AA mixtures were composed by a pharmacist
and delivered within an aqueous suspension. In order to
reduce the risk of undesired lump formation, the crystal-
line amino acids were solubilized as much as possible with
a low sugar substitute in an amount of 200 ml of water
using a milk frother. Beverage intake period was reduced
to a minimum of approximately 3 min. The sample was
divided into four randomized and counterbalanced
groups of 18 people with equal gender distributions
(9 women and 9 men). The administration of the different
AA beverages was counterbalanced for sex. Participants
of each group either received ATD, BAL, ATDPHE/LEU, or
BALPHE/LEU.
The neurodietary challenge procedure ATD Moja-De
was previously used successfully with children and ado-
lescents and had few side effects due to the administration
regimen that adapted dosage to body weight (26, 3638,
4144). The dosage per 10 kg of body weight contained
L-PHE (1.32 g), L-LEU (1.32 g), L-ILE (0.84 g), L-MET
(0.5 g), L-VAL (0.96 g), L-THR (0.6 g), and L-LYS
(0.96 g). TRP (0.7 g per 10 kg of body weight) was added
to the corresponding control condition (BAL). The newly
developed AA mixture (ATDPHE/LEU), also dosed per
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10 kg of body weight, consisted only of L-PHE (3.2 g) and
L-LEU (3.0 g); BALPHE/LEU, the new mixture’s control
condition, contained an additional dose of 0.7 g of TRP
per 10 kg of body weight.
Blood samples
Blood samples (BS) were collected using a permanent
venous catheter at baseline (T0) and each hour (T1, T2, T3,
T4, T5, and T6) after the intake of ATD, BAL, ATDPHE/
LEU, or BALPHE/LEU (BS0, BS1, BS2, BS3, BS4, BS5, and
BS6), resulting in seven blood samples per subject. A 9-ml
Ethylenediaminetetraacetic acid (EDTA-Tube) (EDTA S-
Monovette†, Sarstedt, Germany) and one 7.5-ml Serum-
Tube (Serum S-Monovette†, Sarstedt, Germany) were
used for sample collection each hour. To avoid falsification
of the blood values, the first 4.5 ml of every sample was
rejected. The collected blood samples were kept at room
temperature for 20 min and centrifuged at 2,500 g for 10
min. The resulting clear supernatant was removed with a
pipette and kept in 2-ml Eppendorf Tubes† at 808C
until transportation to the laboratory.
For the TRP influx calculations, plasma levels of PHE,
Tyrosine (TYR), and TRP were measured using enzyme-
linked immunosorbent assay (ELISA) kits (Immundiag-
nostik AG, Bensheim, Germany) in accordance with the
manufacturer’s instructions. The detection of the branched-
chained AAs (BCAA: LEU, ILE and VAL) concentration
using a BCAA test kit (Immundiagnostik AG, Bensheim,
Germany) for photometric analyses of enzyme levels in
plasma and serum was carried out according to the
manufacturer’s instructions. Information regarding sensi-
tivity and specificity of the employed test kits is provided
in Supplementary Table 1.
Influx calculation into the brain for TRP, TYR, and PHE
We calculated the influx of TRP across the BBB using
MichaelisMenten kinetics with a correction for multiple
substrate competition, which is an established procedure in
ATD-related research (16, 45). As the competitive sub-
strate inhibition of TRP and the LNAAs at the common
transporting enzyme L-1 determines the uptake of TRP
into the brain, this equation provides a valid mathematical
model for calculating the unidirectional TRP influx rates
into the central nervous system (26, 36, 46). The equation
(see Supplementary file) includes both components influ-
encing TRP uptake: the facilitated diffusion of AAs at L-1
and passive diffusion (36). Influx rates of the competing
LNAAs PHE, TYR, as well as BCAA influx were
calculated using the same equation. In addition to the
abovementioned influx calculations, we also provided the
following ratios to ensure comparability with previous
ATD studies: [TRP]/[CAA], [TYR]/[CAA], [PHE]/[CAA],
and [PHETYR]/[BCAATRP] (CAAcompeting
amino acids). These ratios predict the entry rates of the
involved amino acids into the brain and present another
possible approach for evaluating ATD protocols.
Questionnaires
Mood
The German version of the Positive and Negative Affect
Schedule (PANAS) (47) containing 10 items for positive
(PA) and 10 items for negative (NA) affect was used to
measure the extent to which depletion influenced the
subjects’ mood state. Participants rated the intensity of
each item on a five-point Likert scale (from 1not at all
to 5very much) at baseline and every hour before the
collection of the blood samples.
Challenge tolerance
We developed an in-house questionnaire on the tolerance
of the AA challenges to detect if the newly developed
mixture caused an equal amount of side effects as the
established ATD Moja-De procedure. The questionnaire
contained 12 items rated from 0 (disagree) to 3 (strongly
agree). For evaluation purposes, we summarized the
matching items and calculated a somatic complaints score,
an awakeness score, and a hunger score. The common side
effects observed in previous ATD studies, namely, headache,
Table 1. Descriptive data of the study sample
ATD BAL ATDPHE/LEU BALPHE/LEU
Age M9SD 23.1192.89 23.9493.15 23.6792.66 23.7293.69
Min. 18 18 18 19
Max. 30 32 29 33
IQ M9SD 107.67916.36 113.22912.10 114.61914.97 112.89910.27
Min. 80 97 76 97
Max. 138 142 142 134
BMI M9SD 22.9092.53 22.1892.81 22.2192.52 22.2592.41
Min. 18.8 17.9 19.4 18.8
Max. 27.3 29.0 29.4 26.9
Descriptive data of the study sample are divided into four conditions/groups: acute tryptophan depletion mixture Moja-De (ATD), the TRP-balanced
control condition for ATD Moja-De (BAL), the new ATD amino acid mixture (ATDPHE/LEU), or the newly developed control condition for ATDPHE/LEU
(BALPHE/LEU). Mean9standard deviation (M9SD), maximum (Max.), and minimum (Min.) values are listed for age, IQ, and body mass index (BMI).
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nausea, vomiting, dizziness, and sweating (48), were in-
cluded in this questionnaire (the entire questionnaire is
available in the Supplementary file). Participants com-
pleted this questionnaire every hour and immediately
before and after the intake of the AA beverages.
Taste
For taste evaluation, an in-house questionnaire consist-
ing of six items was employed (see Supplementary file).
The consistency, the sulfuric taste, the difficulty of intake,
and revulsion were assessed using a scale of 0 (disagree)
to 3 (strongly agree) immediately after the intake of the
AA beverages.
Statistical analysis
As primary analysis, the influence of the four different
AA mixtures on TRP influx across the BBB was in-
vestigated using repeated measures analyses of variance
(rmANOVAs) with treatment as the between-subjects
factor, time as the within-subjects factor, and gender as a
covariate in SPSS Version 21.0 for MacOS. The degrees
of freedom for the ANOVA F-statistics were adjusted
according to the GreenhouseGeisser correction for non-
sphericity (pB0.05). Similar analyses were performed on
TYR and PHE influx across the BBB, on [TRP]/[CAA]
ratio, on tolerance (the somatic complaints score, awake-
ness score, and hunger score), and on the PA- and NA-
PANAS scores over time. In addition, separate ANOVAs,
with the GreenhouseGeisser correction, on the TRP
influx for each group using time as a within-subjects
factor were performed. One-way ANOVA was used to
determine any significant differences in [TRP]/[CAA]
ratio, in TRP, TYR, and PHE influx rates between the
groups at baseline (T0). The influences of the different
side effects (e.g. headache, nausea, vomiting, dizziness,
and sweating), part of the somatic complaints score, were
assessed by rmANOVAs with time as the within-subjects
factor and treatment as the between-subjects factor.
One-way ANOVA with gender as a covariate was em-
ployed to analyze taste differences between the four
mixtures. Gaussian distribution for all dependent vari-
ables was established with the KolmogorovSmirnov test
for each of the four groups and for the groups formed by
dividing the participants by gender. The level of statistical
significance was set and kept at pB0.05. Because of the
explorative nature of this study, alpha-adjustment was
not employed. Post hoc power analyses were performed
using G*Power Version 3.1.9.2. for MacOS.
Results
All plasma AA concentrations of TRP, PHE, TYR, and
BCAA are presented in Table 2. Table 3 includes all cal-
culated influx values for TRP, TYR, PHE, (TYRPHE),
and BCAA across the BBB.
TRP influx into the brain
No significant differences in TRP influx were present at
baseline (T0) when comparing ATD, BAL, ATDPHE/LEU,
and BALPHE/LEU (F[3, 71]2.005; pn.s.). An rmANOVA
yielded main effects of time (F[3.801, 258.437]69.972;
pB0.001) and group (F[3, 68]97.577; pB0.001) and a
significant time by group interaction (F[11.402, 258.437]
25.875; pB0.001). Bonferroni post hoc analyses indi-
cated significant differences between each of the four
groups (mean TRP influx BALBALPHE/LEUATD
ATDPHE/LEU; see Supplementary Tables 2 and 3 for
detailed results). The comparison of the influx curves for
all groups is given in Fig. 1a. Separate rmANOVAs with
time as the within-subjects factor indicated a main effect of
time for each group. Table 4 summarizes the degrees of
freedom (df) and F- and p-values of these analyses. Time
points of maximum TRP influx decline (Tmax), maximum
decline in TRP influx in relation to baseline (Declinemax),
and overall TRP influx declines from baseline to time
point T6 for each group are given in Table 5. Maximum
decrease in TRP influx 4 h after intake was 11.9% higher
for ATDPHE/LEU compared with the decrease found for
ATD. In contrast to ATD, ATDPHE/LEU, and BALPHE/LEU
administration, a significant increase in TRP influx was
detected in the BAL condition control group during the
first 60 min after beverage administration (p0.002),
while no significant changes in influx rates were detected
over the entire period from T0 to T6. No effect of gender
was detected (F[1, 67]2.537; pn.s.). Post hoc power
analysis showed that our study was adequately powered
(power of 0.95) to detect effect sizes of 0.25 with an alpha
level of 0.05 using a between-subjects repeated measures
approach (ANOVA). In addition, we calculated Cohen’s
d-values as an estimate for effect sizes (d-value of d0.24
for the comparison of TRP-influx after ATD versus
BAL administration; d0.14 for the comparison of
ATDPHE/LEU and BALPHE/LEU).
TYR and PHE influx into the brain
An rmANOVA on TYR influx rates indicated main
effects of time (F[2.122, 144.270]226.885; pB0.001) and
group (F[3, 68]11.191; pB0.001) and a significant time
by group interaction (F[6.365, 144.270]2.255; p0.038).
Bonferroni post hoc analyses indicated that only ATD
showed significant difference from the other three treat-
ment conditions, while no significant difference could be
found between the three of them. With regard to TYR
influx, the curve progression for all treatment conditions
was overall comparable with a strong decrease in TYR
influx during the first hour (see Fig. 1b). While TYR influx
after ATD administration was maximally decreased by
48% of the baseline value, influx after ATDPHE/LEU
displayed a decrease of 71%. Similar analyses for PHE
influx values also showed main effects of time (F[3.849,
261.745]204.575; pB0.001) and group (F[3, 68]77.348;
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pB0.001) and a significant time by group interaction
(F[11.548, 261.745]2.255; pB0.001). Bonferroni post hoc
analyses indicated significant differences between all
groups, except of ATDPHE/LEU versus BALPHE/LEU that
did not present any significant results. PHE influx curves
for all groups can be found in Fig. 1c. For ATDPHE/LEU
and BALPHE/LEU, PHE influx values showed an increase
during the first 4 h, followed by only a small decrease
until T6 (ATDPHE/LEU: maximum increase by 159% of
baseline; BALPHE/LEU: maximum increase by 179% of
Table 2. Blood concentrations of tryptophan, phenylalanine, tyrosine, and BCAA
Parameter Mixture Baseline (T0) T1 T2 T3 T4 T5 T6
[TRP] in mmol/l ATD 7093 117922 111923 95922 83922 75923 69917
BAL 6893 418922 437923 393922 372922 261923 178917
ATDPHE/LEU 6693 107922 110923 111922 108922 105923 97917
BALPHE/LEU 6893 460922 407923 422922 409922 397923 308917
[PHE] ATD 51924 376953 484992 393996 4199117 3139118 2429115
BAL 55924 329953 400992 330996 3109117 2849118 1929115
ATDPHE/LEU 112924 972953 1236992 1457996 15719117 14279118 11829115
BALPHE/LEU 86924 977953 1474992 1816996 19269117 16839118 14169115
[TYR] ATD 5994 10898 120913 109914 100914 94915 88912
BAL 5594 9798 97913 85914 79914 71915 60912
ATDPHE/LEU 5994 13298 170913 193914 204914 197915 189912
BALPHE/LEU 6294 13098 169913 195914 207914 206915 196912
[BCAA] ATD 416920 1444953 1458956 1374961 1251957 1040964 819947
BAL 412920 1278953 1297956 1249961 1137957 905964 744947
ATDPHE/LEU 405920 1078953 971956 953961 822957 628964 485947
BALPHE/LEU 400920 1024953 945956 973961 827957 604964 446947
Plasma amino acid concentrations (in mmol/l) of tryptophan, phenylalanine, tyrosine, and branched-chain amino acids (BCAA; including valine, leucine,
and isoleucine) after the administration of four different amino acid mixtures: ATD (acute tryptophan depletion; challenge condition), BAL (control
condition for ATD), ATDPHE/LEU (newly developed challenge condition), and BALPHE/LEU (control condition for ATDPHE/LEU). Mean values9standard
error are given for the different groups (each including 18 subjects) at the seven time points of blood withdrawal (T0T6).
Table 3. Calculated influx values of particular amino acids across the BBB
Parameter Mixture Baseline (T0) T1 T2 T3 T4 T5 T6
TRP-influx ATD 13.57390.479 6.91290.603 6.00490.609 5.71590.645 4.89790.637 5.48590.752 6.45290.552
BAL 13.31390.479 17.19090.603 16.53390.609 16.82190.645 16.86490.637 14.12290.752 14.23690.552
ATDPHE/LEU 12.13590.479 3.96990.603 3.43490.609 3.12590.645 2.93490.637 3.15590.752 3.55790.552
BALPHE/LEU 12.48390.479 12.44990.603 9.48390.609 8.82890.645 8.43590.637 8.93990.752 8.19190.552
TYR-influx ATD 5.64790.297 2.99790.167 3.00290.173 3.13990.173 2.91190.189 3.51490.266 4.07890.311
BAL 5.33890.297 2.05490.167 1.86690.173 1.87790.173 1.92190.189 1.95990.266 2.52390.311
ATDPHE/LEU 5.21390.297 1.90590.167 2.03890.173 1.96490.173 2.02290.189 2.28590.266 2.76590.311
BALPHE/LEU 5.46490.297 1.51590.167 1.53090.173 1.50190.173 1.58290.189 1.85990.266 2.34890.311
PHE-influx ATD 10.39190.630 18.34290.628 19.73390.918 18.71990.981 19.49391.120 18.00891.219 16.97591.119
BAL 10.81990.630 14.70690.628 16.09190.918 14.76490.981 14.54091.120 14.52291.219 14.08891.119
ATDPHE/LEU 12.23490.630 26.22990.628 28.66190.918 30.62790.981 31.64291.120 30.49391.219 28.37891.119
BALPHE/LEU 11.97890.630 24.25090.628 29.41190.918 32.38790.981 33.42891.120 31.32191.219 29.32591.119
BCAA-influx ATD 11.96890.453 15.58290.448 15.11290.501 15.50290.570 14.34090.544 14.01890.612 12.90190.435
BAL 11.73690.453 12.19890.448 11.69290.501 12.09290.570 11.57090.544 10.24590.612 10.80990.435
ATDPHE/LEU 10.93790.453 8.50590.448 7.13190.501 6.52490.570 5.58790.544 4.46490.612 3.87290.435
BALPHE/LEU 10.81490.453 7.35290.448 6.17190.501 5.96890.570 5.04490.544 3.95890.612 3.16490.435
Calculated influx values (in nmol/min/g brain tissue) for tryptophan (TRP), tyrosine (TYR), phenylalanine (PHE), and branched-chain amino acids
(BCAA; including valine, leucine, and isoleucine) across the blood-brain barrier after the administration of four different amino acid mixtures: ATD
(acute tryptophan depletion; challenge condition), BAL (control condition for ATD), ATDPHE/LEU (newly developed challenge condition), and BALPHE/
LEU (control condition for ATDPHE/LEU). Mean values9standard error are presented for the different groups (each including 18 subjects) at the seven
time points of blood withdrawal (T0T6).
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baseline). In comparison, a much smaller increase of PHE
influx appeared after ATD (maximum increase by 89% of
baseline) and BAL (increase by 49% of baseline) adminis-
tration.
[TRP]/[CAA]
Figure 2 shows the time course of [TRP]/[CAA] ratios for
the four treatment conditions, which offers a comparable
development with regard to TRP influx calculations, but
with a focus on plasma concentrations. No significant
differences in the ratios were present at baseline (T0) when
comparing ATD, BAL, ATDPHE/LEU, and BALPHE/LEU
(F[3, 71]0.898; pn.s.). An rmANOVA yielded main
effects of time (F[4.213, 286.489]5.447; pB0.001) and group
(F[3, 68]73.368; pB0.001) and a significant time by group
interaction (F[12.639, 286.489]17.960; pB0.001). Bonferroni
post hoc analyses indicated significant differences between
each of the four groups except of no significant result for
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Fig. 1. (a, b, c) Influx curves (nmol/min/g brain tissue) of tryptophan (TRP), tyrosine, and phenylalanine across the blood-brain
barrier at baseline (T0) and time points T1T6 after the intake of the ATD Moja-De amino acid (AA) mixture, its balanced
control condition (BAL), the newly developed tryptophan depletion protocol ATDPHE/LEU, and the corresponding control
condition (BALPHE/LEU). Data are given as the mean values, with bars representing the standard errors.
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ATD and ATDPHE/LEU. Maximum decrease in [TRP]/[CAA]
ratio is reached 4 h after intake (T4) for both protocols.
ATD and ATDPHE/LEU reduced the ratio by 66 and 65%,
respectively, when compared with baseline. Values of all
calculated ratios are given in Table 6, and additional
graphs for [TYR]/[CAA] and [PHE]/[CAA] ratios of all
groups are presented in Supplementary Fig. S1a and S1b.
Taste
One-way ANOVA of the taste evaluation scores with
gender as a covariate yielded no significant difference in
taste perceptions between the groups (F[3, 67]0.997;
pn.s.) and no effect of gender (F[1, 67]0.102; pn.s.).
Challenge tolerance
An rmANOVA evaluation of challenge tolerance indicated
a main effect of time for the analysis of the hunger score
(F[4.760, 314.190]4.457; p0.001); post hoc testing indi-
cated a significant increase in hunger from baseline (T0) to
T6 (p0.001). Similar analyses of the awakeness score also
yielded a main effect of time (F[4.182, 275.991]9.741;
pB0.001). Within the 6 h from baseline (T0) to T6,
the awakeness score decreased significantly (p0.001),
but participants felt most tired at T2. The main effects
of time (F[4.018, 265.208]5.077; p0.001) and group
(F[3, 66]3.939; p0.012) were detected for the somatic
complaints score and indicated an increase in somatic
complaints over time. Bonferroni post hoc analyses
showed a significant difference between BALPHE/LEU
and BAL administration (p0.012). The average somatic
complaints score related to BALPHE/LEU administration
(average score 0.70890.117) was four times greater than
the values reported by the BAL condition group (average
score 0.16990.121). While the participants overall
felt more unwell 2 h (T2) after the intake of the
AA mixtures (p0.022), the somatic complaints scores
decreased from T2 to T4 (p0.002), with only a slight,
non-significant increase observed at T6 compared with
the baseline score. At baseline, there were no significant
differences in somatic complaints scores between the
groups (F[3, 68]0.169; pn.s.). Analyses of each indivi-
dual item in the somatic complaints score showed
a comparable development of nausea. The report of
nausea significantly increased from T0 to T2 (p0.046)
and then significantly decreased from T2 to T4 (p0.014).
No gender effects were detected in the hunger (F[1, 65]
0.192; pn.s.), awakeness (F[1, 65]0.769; pn.s.), or
somatic complaints scores (F[1, 65]0.179; pn.s.).
Mood assessment (PANAS)
An rmANOVA of the PA score showed a main effect
of time (F[3.335, 220.091]54.110; pB0.001), but no signifi-
cant effect of group (F[3, 65]0.215; pn.s.) or gender
(F[1, 65]0.933; pn.s.). Compared with the base-
line score, a decrease in the PA score of 28.5% at
T6 was observed (pB0.001). The NA score also
decreased (11.4% from baseline to T6; F[3.198, 211.086]
12.502; pB0.001, rmANOVA) regardless of gender
(F[1, 65]0.268; pn.s.).
Discussion
The results of this pilot study indicate that dietary
administration of ATDPHE/LEU led to a greater depletion
magnitude with regard to the TRP influx across the BBB
compared with the depletion observed when using the
ATD Moja-De protocol, but not with regard to plasma
TRP concentrations because of an unintended initial
short increase in plasma TRP concentrations that was
observed after ATDPHE/LEU intake (see further below
in this section for a discussion). The found effect on
TRP influx across the BBB was observed even though
ATDPHE/LEU, which consisted of only two AAs (PHE
and LEU), was administered in a lower overall AA dose.
Participants evaluated the tolerance level of the new
AA challenge beverage as acceptable. No situations or
events necessitating premature termination of the study
occurred (such as participants vomiting during measure-
ments or other incidents affecting ratings). Thus, several
criteria for a potentially valid and effective ATD-test
protocol were already achieved, while other aspects such
as the observed unexpected increase in plasma TRP levels
Table 4. Results of rmANOVA on tryptophan influx values
ATD BAL ATDPHE/LEU BALPHE/LEU
df 2.130, 36.206 3.136, 53.314 1.269, 21.579 4.057, 68.962
F 86.110 7.646 120.067 20.645
p B0.001 B0.001 B0.001 B0.001
Results of separate repeated measurements analyses of variance
(rmANOVAs) on tryptophan (TRP) influx across the blood-brain
barrier for ATD (challenge condition), BAL (control condition for
ATD), ATDPHE/LEU (newly developed challenge condition), and BALPHE/
LEU (control condition for ATDPHE/LEU), with time as the within-subjects
factor. df, degrees of freedom; F, F values; p, statistical significance.
Table 5. Descriptive data of tryptophan depletion graphs
ATD BAL ATDPHE/LEU BALPHE/LEU
Tmax (min) 240 60 240 360
Declinemax (%) 63.9 29.1 (increase) 75.8 34.4
DeclineT0-T6 (%) 52.5 6.9 (increase) 70.7 34.4
Time points of maximum tryptophan (TRP) influx decline (Tmax), maximum
declines of TRP influx in relation to baseline (T0) (Declinemax), and overall
TRP influx declines from baseline (T0) to time point T6 (time point of last
blood sample) for the groups ATD (challenge condition), BAL (control
condition for ATD), ATDPHE/LEU (newly developed challenge condition), and
BALPHE/LEU (control condition for ATDPHE/LEU).
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require further improvements and future studies in order
to validate the findings of the current pilot study.
The altered composition of ATDPHE/LEU, including
only two AAs, in contrast to the ATD Moja-De that
includes seven different AAs, should lead to a greatly
simplified production of the AA beverage. Moreover,
it also enables facilitated monitoring of relevant blood
parameters (i.e. AA concentrations) as their number was
consequently reduced. Such monitoring was further sim-
plified by the development and use of ELISA and BCAA
test kits (Immundiagnostik AG, Bensheim, Germany).
ATDPHE/LEU uses the same body weight-adapted dosing
regimen of the ATD AA mixtures that was first success-
fully applied in the ATD Moja-De protocol (36, 37). This
well-tolerated dosing regimen is based on the assumption
of a positive correlation between body weight and plasma
TRP levels (36, 37) and, as a significant advantage, leads
to a possible application for children and adolescents
with fewer side effects (4244, 49, 50).
The greater effectiveness of ATDPHE/LEU in terms of a
greater reduction in TRP influx across the BBB when
compared with ATD Moja-De could be seen as an
advantage, whereas the found effects on plasma TRP
concentrations require further investigation. The reason
for the detected effects on TRP influx into the brain may
lie in the different affinities of the LNAAs to the common
L-1 transporter. The Michaelis constant (KM) represents
a measurement of these particular affinities. Precisely, it
is indicative of the specific substrate concentration
needed to achieve the half-maximal rate of turnover of
an enzyme. Thus, a lower KM value of a substrate is
associated with its higher affinity to the related enzyme.
Smith et al. (16) determined the values of transport con-
stants for seven LNAAs, including PHE (0.011 mmol ml1)
and LEU (0.029 mmol ml1), in anesthetized rats. It must
be acknowledged that transferring findings from rodent
research to humans is subject to limitations. However, these
values for the respective transport constants can serve as
a first rough estimate, and the high and significant positive
correlations between TRP influx and the TRP/CAA ratio
(a previous measure for the effects of ATD) are consistent
with the theoretical considerations for using Michaelis
Menten kinetics to characterize TRP influx across the
BBB. The high affinity of PHE and LEU to L-1, compared
BALPHE/LEU
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Fig. 2. Curve progression for calculated TRP/CAA ratios from baseline (T0) to time point T6 after the intake of the ATD Moja-
De amino acid (AA) mixture, its balanced control condition (BAL), the newly developed tryptophan depletion protocol
ATDPHE/LEU, and the corresponding control condition (BALPHE/LEU). Data are given as the mean values, with bars
representing the standard errors.
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with all other LNAAs, may have caused the best displace-
ment of TRP at the common transporter and therefore was
possibly associated with a greater reduction of TRP influx
across the BBB. By contrast, the ATD Moja-De, contain-
ing a mixture of seven different AAs with partly lower KM
values, was less effective with regard to the competition of
the AAs against TRP, resulting in a smaller TRP depletion
magnitude in terms of TRP influx across the BBB
compared with the ATDPHE/LEU depletion magnitude. It
is possible that the use of this competitive mechanism in
the respective AAs enables the potential effectiveness of
TRP depletion after ATDPHE/LEU administration, despite
the simultaneous reduction in the overall AA dose and
thus a possibly decreased stimulation of protein synthesis
in the liver when compared to other ATD protocols. This
could have impacted the observed findings with regard to
changes in plasma TRP concentrations and a possible
redistribution between free and protein-bound TRP. The
observed TRP influx curves of the old and new challenge
protocols over the entire study duration resulted in
maximum depletion in terms of decreased TRP influx
across the BBB at 4 h after intake for both challenge
procedures. In particular, TRP influx correlated highly
and significantly with the TRP/CAA ratio for both ATD
challenge conditions used (see Supplementary Tables S5
and S6 and Fig. S2a and S2b), but the influx rates are
likely to be a more adequate reflection of TRP availability
in the brain as they also take the individual affinities of
the different amino acids to the L-1 transport system at
the BBB into account.
It is important to keep in mind that this workonly claims
to be a first pilot study. Therefore, the assessment of brain
TRP and 5-HT concentrations after ATDPHE/LEU applica-
tion in rodents has to be an essential part of future research
as well as PET-studies and the measurement of
5-hydroxyindoleacetic acid (5-HIAA) concentrations
(the primary metabolite of 5-HT) in human cerebrospinal
fluid in order to validate the effectiveness of ATDPHE/LEU
revealed by this study. A recent study by Sa´nchez et al. (12)
has provided preliminary evidence for the effectiveness of
simplified ATD protocols using a three-AA-formulation
(PHE, LEU, and ILE); however, future studies in humans
assessing cerebrospinal fluid (CSF) 5-HIAA concentra-
tions after intake of the challenge procedure are needed.
The absence of any gender effects in the blood para-
meters was an expected outcome. Although central
nervous 5-HT synthesis is known to significantly differ
in males and females (51), we monitored peripheral TRP
and LNAA plasma levels for TRP influx calculations;
these parameters are not influenced by gender-specific
alterations in TRP influx and related central nervous
5-HT synthesis. The performed power analyses confirmed
that this study was adequately powered to detect small
effects, and Cohen’s d calculations indicated small esti-
mates for effect sizes for the analyses conducted.
Specificity for depleting central nervous 5-HT synthesis
(in particular with regard to possible effects on dopamine
and other neurotransmitters) is always an important point
to be considered with regard to all available ATD-related
amino acid formulations. Previous research from our
Table 6. Amino acid ratios
Parameter Mixture Baseline (T0) T1 T2 T3 T4 T5 T6
[TRP]/[CAA] ATD 0.13490.006 0.06390.013 0.05590.012 0.05190.014 0.04690.014 0.04990.014 0.05790.010
BAL 0.13590.006 0.25190.013 0.24890.012 0.24790.014 0.25390.014 0.20490.014 0.18690.010
ATDPHE/LEU 0.12390.006 0.05090.013 0.04790.012 0.04490.014 0.04390.014 0.049390.014 0.05790.010
BALPHE/LEU 0.12990.006 0.22590.013 0.16890.012 0.15890.014 0.15590.014 0.17290.014 0.16290.010
[PHE]/[CAA] ATD 0.09490.043 0.23290.037 0.32090.078 0.29390.077 0.32990.087 0.30890.117 0.25490.139
BAL 0.10290.043 0.18290.037 0.22090.078 0.19390.077 0.19390.087 0.21390.117 0.19190.139
ATDPHE/LEU 0.20690.043 0.75990.037 1.03990.078 1.18390.077 1.39990.087 1.54890.117 1.56190.139
BALPHE/LEU 0.16390.043 0.61090.037 0.95290.078 1.15590.077 1.33490.087 1.40390.117 1.46290.139
[TYR]/[CAA] ATD 0.10890.006 0.05690.004 0.05990.004 0.05990.005 0.05990.006 0.06890.009 0.08190.012
BAL 0.10390.006 0.04890.004 0.04690.004 0.04390.005 0.04590.006 0.04790.009 0.05690.012
ATDPHE/LEU 0.10590.006 0.06390.004 0.07590.004 0.07990.005 0.08690.006 0.10390.009 0.12490.012
BALPHE/LEU 0.11290.006 0.05490.004 0.06290.004 0.06390.005 0.07090.006 0.08590.009 0.11290.012
[PHETYR]/ ATD 0.22690.051 0.31890.043 0.42890.093 0.40590.093 0.44790.103 0.45190.145 0.39590.194
[BCAATRP] BAL 0.22990.051 0.25090.043 0.28990.093 0.25590.093 0.25790.103 0.28590.145 0.27090.194
ATDPHE/LEU 0.35990.051 0.96390.043 1.37390.093 1.59490.093 1.92790.103 2.26890.145 2.45090.194
BALPHE/LEU 0.31390.051 0.75690.043 1.18890.093 1.45290.093 1.72390.103 1.88290.145 2.09690.194
Ratios of tryptophan, phenylalanine, tyrosine, and branched-chain amino acids (BCAA; including valine, leucine, and isoleucine) and their competing
amino acids (CAA) after the administration of four different amino acid mixtures: ATD (acute tryptophan depletion; challenge condition), BAL (control
condition for ATD), ATDPHE/LEU (newly developed challenge condition), and BALPHE/LEU (control condition for ATDPHE/LEU). Mean values9standard
error are given for the different groups (each including 18 subjects) at the seven time points of blood withdrawal (T0T6).
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group indicated that the Moja-De protocol does not affect
central nervous dopamine synthesis in mice (38).
As such evidence is currently missing for the newly de-
veloped protocol ATDPHE/LEU, we looked at TYR and
PHE plasma values and their calculated influx into the
brain. The strong decrease in TYR influx after challenge
application, as described above, questions the specificity
of the newly developed ATDPHE/LEU condition. The
phenomenon of highly increasing PHE influx values in
the ATDPHE/LEU protocol group can be explained by
its high PHE concentrations. As the strong decrease
in TYR influx indicates, the high PHE dose does not
mitigate the decrease in TYR influx (calculated from
peripheral blood values). Whether the high PHE amount
in the ATDPHE/LEU mixture directly affects central
nervous concentrations of TYR formation can only be
answered using future neurochemical challenge studies.
However, specificity for respective neurotransmitters
is always a critical issue when dealing with different
TRP depletion protocols. This is a general problem in
ATD-related research in humans and affects all currently
available ATD amino acid formulations. Badawy et al.
(52) provided an approach to enhance ATD formulations’
specificity by decreasing the amount of BCAAs. In
accordance with this, the reduction of the LEU amount
in our newly developed ATDPHE/LEU protocol might be
a potential avenue for future research. An unintended
rather substantial increase in plasma TRP was observed
after ATDPHE/LEU intake besides the fact that no TRP
was ingested, and future studies are needed to investigate
and replicate this unknown effect. Protein synthesis can be
stimulated by the ingested amino acids, which in turn
might have led to a possible redistribution between free
and protein-bound TRP. Following this train of thought,
the amount of free TRP possibly was slightly higher
while the overall balance remained unaffected. It also
needs to be outlined that TRP-related metabolites, such
as quinolinic acid, kynurenic acid, and tryptamine that
can be changed due to administration of the balanced
mixture, can influence brain function. This stands in line
with the issue of the specificity of all ATD/BAL para-
digms currently available. Finally, the reason why the
fasting TRP levels (T0) were higher than those mentioned
in the literature is not clear but worth noting and might be
specific to the investigated sample.
Another issue regarding our new ATD challenge pro-
tocol is the absence of an appropriate control condition
that ‘maintains baseline values without altering the bio-
chemical or behavioral parameters’ (52). The observed rise
in TRP influx approximately 1 h after administration of
the BAL control condition seems to be a logical conse-
quence of the enhanced TRP availability because the BAL
mixture contained TRP. For this particular reason, the
decline in TRP influx of 34.4% after BALPHE/LEU admin-
istration over the 6-h period appears to be counterintuitive.
When comparing BALPHE/LEU with its challenge con-
dition ATDPHE/LEU, the administration of BALPHE/LEU
led to a depletion of approximately 50% in magnitude of
the depletion observed following ATDPHE/LEU adminis-
tration. The large amount of PHE in the BALPHE/LEU
mixture may be a possible explanation for this par-
ticular phenomenon, which in turn could lead to an
unexpected increase in displacement of TRP at the BBB
in this control condition. To address this particular
problem, either an increase in TRP or decreased levels
of PHE or LEU in the control condition could be
evaluated in future research in order to establish a valid
control condition for ATDPHE/LEU.
Both protocols that were applied in this study, ATD and
BAL on the one hand and ATDPHE/LEU and BALPHE/LEU
on the other hand, were well tolerated by the subjects. In
particular, we did not observe any headaches, vomiting,
dizziness, or sweating as indicated by the itemizing analy-
ses of our somatic complaints score (see Supplementary
Table S3). There were no dropouts caused by side effects.
Hence, this requirement of a valid test protocol was met.
Although we could not observe a significant group
effect for the somatic complaints score between ATD
and ATDPHE/LEU indicating a reduction of side effects
in the new challenge condition, we achieved the goal
of maintaining the high-grade safety of the established
ATD Moja-De.
The monitored increase in hunger throughout the
study day most likely resulted from the 6-h abstinence
from food and a breakfast overall low in nutrition. The
lack of any group effect in hunger ratings supports
the previous assumption. This observation justifies the
necessity of the low-protein breakfast at the beginning of
the study day. However, although its carbohydrate content
can, to some extent, affect plasma TRP concentration and
binding and levels of BCAA, it would not be justifiable to
demand fasting beginning at 8 p.m. the night before the
study day till 3 p.m. on the study day. Furthermore, the
collection of additional behavioral, cognitive, and emo-
tional data during this study for future analysis would
have been likely to be skewed by significant fasting effects if
no breakfast had been given. In this context, a variety of
ATD-using studies also administer low-protein meals
during the depletion procedure (5356). In the present
sample, we attribute the occurrence of increasing tiredness
during the study day to external circumstances, such as the
study environment and the long testing period, as opposed
to a side effect of the protocol. The missing group effect can
be seen as somewhat indicative for this phenomenon.
Moreover, breakfast intake could also have impacted side
effect ratings as assessed within the present study.
As stated above, we found an effect of group and
time for the somatic complaints score. In the separated
item analyses, nausea is the only side effect showing a
main effect of time and displays an equal development.
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Although few ATD studies focused on the examination
of side effects, nausea appears to be a frequent problem
in these particular studies (31, 48). It is very likely that
the ingestion of a substantial amount of crystalline
AAs (Moja-De: 6.5 g/10 kg body weight, ATDPHE/LEU
6.2 g/10 kg body weight) that remain in the stomach until
dissolution in the acidic environment contributed to
the reports of nausea (57). The missing group effect in
somatic complaint investigations partially supports this
assumption because all groups were equally affected.
Moreover, post hoc analyses of the somatic complaints
scores revealed a significant difference between BAL
and BALPHE/LEU administration as a group effect with
an average somatic complaints score four times greater
after BALPHE/LEU intake. However, with a maximal
somatic complaints score of 24 and a minimal score of
0, the very low mean value observed in this study was
not indicative of the intolerability of the new control
condition. A modification of the BALPHE/LEU control
condition, as mentioned above, might help improve
the side effect profile of BALPHE/LEU.
Presently, there is no ATD-specific validated ques-
tionnaire available for somatic complaint or taste assess-
ment. This study provides first questionnaire-based pilot
data and certainly requests validation in future ATD
studies. In particular, further refinement is needed
regarding the gradual and sensible detection of symptom
nuances.
Both positive (PA) and negative (NA) PANAS assess-
ments decreased over the 6-h study duration. In addition
to these controversial findings, no group effect was
detected, which suggests that the ratings were influenced
by the situation during measurements and, perhaps, not a
direct consequence of altered brain 5-HT function. This
is in agreement with previous findings which suggested
that ATD’s influence on mood was largely dependent
on the susceptibility of the study sample, and this vari-
ability led to a lack of clear mood effects in many cases
(58, 59). However, the assessment of mood only served
as an ancillary controlling variable in this study, and
these results do not significantly impact or question its
major findings.
Although subjects took the amino acid mixtures with-
out any major problems and the new mixture was well
tolerated in our study, the uncomfortable palatability
seen in all groups certainly requests further modification
to ensure trouble-free utilization. Bitterness in general is a
problematic issue in all ATD studies as it arises from the
specific biochemical structure of polar and hydrophobic
groups in some amino acids (60). The reduction of the
overall amount and dose as well as the absence of the
worst tasting AAs (i.e. MET, cysteine, and arginine)
might have contributed to an easier administration of
ATDPHE/LEU; however, improvements are still required.
For this particular purpose, we suggest to add some of
the conventional flavoring supplements, such as vanilla,
peppermint, raspberry, and lemonade, with low sugar
substitutes to our challenge procedure.
The between-subjects design is a limitation of this
study. Behavioral paradigms conducted as a part of
this study (the findings will be the subject of further
publications) did not allow for a within-subject repeated
measures design due to possible learning effects; a within-
subjects design could be used in further investigations.
Regarding the use of ATDPHE/LEU in behavioral studies,
the high amount of LEU might present a problem, in
particular as LEU is known to alter glutamate formation
within the leucine-glutamate cycle (61, 62). Since LEU might
also affect various other parameters, a separate analysis of
LEU blood values would be essential to achieve better
knowledge of ATDPHE/LEU’s metabolic consequences. In
this study, we chose the assessment of the BCAAs within a
sum parameter for initial investigations as it provides a cost-
saving alternative. Moreover, a further aspect that should
be considered in future studies would be to add caffeine
withdrawal as an additional exclusion criterion since
caffeine has been shown to induce alterations in seroto-
nergic neurotransmission (63, 64).
The ATD method as a serotonergic challenge tool
was criticized by Van Donkelaar et al. in a review
article (65). Specifically, the authors advised caution in
interpreting the selective serotonergic effect of ATD-
related results, postulating a contribution by various
other non-serotonergic mechanisms to diminished 5-HT
metabolism (e.g. alterations in cerebrovascular blood flow,
stress influence, and metabolic effects). Furthermore, the
missing possibility of direct attribution of ATD-induced
behavioral alterations to changes in 5-HT neuronal
activity was noted. However, many of the suggested
mechanisms and the related hypotheses were based on
limited data and primarily indirect conclusions. Overall,
there is sufficient and convincing evidence that ATD
leads to diminished central nervous 5-HT synthesis. In a
rodent model, Biskup et al. (38) demonstrated substan-
tially impaired brain 5-HT synthesis after ATD Moja-De
administration. Furthermore, they found a lowered
content of 5-HIAA, which is the primary metabolite
of 5-HT, and a consequently reduced 5-HT release.
As summarized and outlined by Crockett et al. (66),
all of the alternative mechanisms suggested in the
aforementioned review would lead to broad attentional
and executive impairments that have not been found
in any ATD study involving humans. In general, we
support the need for further research to gain a solidly
grounded understanding of the underlying mechanisms
of ATD because the extent of contributions of additional
mechanisms cannot be reliably estimated.
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In conclusion, the greater decline in TRP influx rates
across the BBB in healthy adults after the dietary
administration of the newly developed simplified ATD
protocol, ATDPHE/LEU, relative to the established ATD
Moja-De mixture, was the major finding of this study.
The altered composition of ATDPHE/LEU, composed of
only two LNAAs (PHE and LEU), enabled the reduction
in the overall AA amount, had acceptable tolerance,
and ensured simplified blood value monitoring due to the
reduced components. Nevertheless, this work only repre-
sents a first pilot study. Future research is warranted not
only to replicate the present findings (optimally a within-
subject repeated measures design) but also to improve
beverage palatability, its specificity for central nervous
5-HT depletion, and to develop a more suitable balanced
control condition (BALPHE/LEU) without significant
TRP-related depletion effects. The direct proof of re-
duced brain 5-HT synthesis in a rodent model (i.e. 5-HT
concentrations in brain tissue) would be beneficial, as
well as investigations of 5-HIAA levels in human cere-
brospinal fluid in order to further validate the newly
developed ATDPHE/LEU mixture. Moreover, as an addi-
tional step, ATDPHE/LEU requires further study before
administering this mixture to children and adolescents
can be considered. If the remaining questions with regard
to changes in plasma TRP levels, aspects of specificity,
and the respective control condition are clarified, the
simplified composition of ATDPHE/LEU might have the
potential to become an advantageous alternative to
the currently available ATD Moja-De protocol for the
investigation of the physiological and behavioral effects
of reduced central nervous 5-HT synthesis in transla-
tional research. However, at this stage, the newly devel-
oped ATDPHE-LEU mixture needs further validation and
is currently not suitable to specifically study central
nervous 5-HT function in humans, and at this point in
time it cannot replace the ATD Moja-De ATD protocol.
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